Days
Hours
Minutes
Seconds

Program Hybrid Conference

 

 

Location:
THE BANQUET HALL*, 
University Club Western Australia.

*
THE BIGGEST CONFERENCE ROOM AT UNICLUB


Day One


8:00am – 8:30am      Registration and coffee
8:30am – 9:00am      Opening Session

8:30am – 8:40am      Welcome to Perth: Professor Peter Davies, PhD 
                           
(Deputy Vice Chancellor- Research and Innovation, Murdoch University, Perth, Australia)

 

8:40am – 8:50am       Opening: Ralph Martins, PhD   
                           
(Chair in Aging & Alzheimer’s Disease, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Australia)

8:50am – 9:00am       Steve Greenberg, MD, PhD
                           
(Professor of Neurology at Harvard Medical School, Boston, USA)

 

9:00am – 9:45am       Plenary Speech: Professor Colin L Masters MD
                           
(The Florey Institute of Neuroscience and Mental Health, Parkville, Australia)

 

 

Professor Colin L Masters MD

Professor of Dementia Research, The Florey Institute, The University of Melbourne

Title of Speech: “The spectrum of Alzheimer’s disease covers parenchymal and perivascular accumulation of beta amyloid”.


Professor Colin Masters has focused his career on research in Alzheimer’s disease and other neurodegenerative diseases, including Creutzfeldt-Jakob disease. His work over the last 40 years is widely acknowledged as having had a major influence on Alzheimer’s disease research world-wide, particularly the collaborative studies conducted with Konrad Beyreuther in which they discovered the proteolytic neuronal origin of the Aβ amyloid protein which causes Alzheimer’s disease. This work has led to the continued development of diagnostics and therapeutic strategies. More recently, his focus has been on describing the natural history of Alzheimer’s disease as a necessary preparatory step for disease modifying 
therapies

Professor Masters is a Professor of Dementia Research at the Florey Institute, and the University of Melbourne and a consultant at the Royal Melbourne Hospital. His achievements have been recognised by the receipt of many international awards.

 

Contact Details

The Florey Institute of Neuroscience and Mental Health

30 Royal Parade, Parkville, VIC 3010 Australia

Ph: +613 9035 6575

c.masters@unimelb.edu.au

 

Coffee break (15 min)

 

10:00am – 12.30pm   1. Theme (full session) ARIA/CAA-ri
*Moderator: Darshan Ghia, MD, Fiona Stanley Hospital, Western Australia

  • Association of in-vivo microglial activation with MRI markers of CAA , CAAri, and CSF anti-amyloid autoantibody testing: 10 years experience of the iCAB longitudinal Cohort Registry on Spontaneous ARIA
      – Fabrizio Piazza, PhD University of Milano Bicocca, Monza, Italy
  •  
  • Animal models for ARIA

  – Patricia Kelly, PhD, University of Ulster, Coleraine North Ireland

  •  
  • Modelling of MRI changes in ARIA
      – Roxana Aldea, PhD, Roche, Basel, Switzerland

CAA related inflammation- an update  *Virtual
  Ellis van Etten, MD PhD, Leiden University Medical Centre, Leiden, Netherlands

  •  
  • Selected oral abstracts – abstract 1
  • Selected oral abstracts – abstract 2
  • Selected oral abstracts – abstract 3
    (3 x 10 min each)

 

12:30pm – 1:30pm    Lunch break/Poster Viewing

 

1:30pm – 3.00pm     2a. Theme (half-session) Iatrogenic CAA
 *Moderator: Hamid Sohrabi, PhD, Murdoch University, Perth, Australia

  • Acquired cerebral amyloid angiopathy: insight into molecular mechanisms  *Virtual
      – Masahito Yamada, MD, PhD Kudanzaka Hospital, Tokyo, Japan
  •  
  • Iatrogenic CAA: clinical and mechanistic implications
      – Gargi Banerjee, PhD, UCL Institute of Prion Diseases, London, UK
  •  
  • Selected oral abstracts – abstract 1
  • Selected oral abstracts – abstract 2
  • Selected oral abstracts – abstract 3
    (3 x 10 min each)

Coffee break (15 min)

 

  • 3:15pm – 5:00pm     2b. Theme (half-session) D-CAA: Progress to Treatment Trials
  • *Moderator: Mark van Buchem, MD, PhD, Leiden University Medical Centre, Leiden, Netherlands
  •  
    • Developments in MRI biomarkers of (Dutch-CAA
        – Matthias van Osch, PhD, Leiden University Medical Center, Leiden, Netherlands
    •  
    • Dutch-type hereditary CAA: from TRACK D-CAA towards a clinical trial
        – Marieke Wermer, MD, PhD, Leiden University Medical Center, Leiden, Netherlands
    •  
    • Biomarkers for CAA trials
        – Steven Greenberg MD, PhD, Harvard Medical School, Boston, USA
    •  
    • The Family Perspective: The real power of your N
        – (Sanne van Rijn, Dorinda ‘t Hart, Dini Plug) function representative families
    •  
    • Selected oral abstracts – abstract 1
    • Selected oral abstracts – abstract 2
    • Selected oral abstracts – abstract 3
  • (3 x 10 min each)

 

5:00pm – 6:00pm     Poster Viewing

 

6:30pm – 11:00pm    Conference Dinner and networking Event:



Day Two

 

8:00am – 9:00am    Poster Viewing

9:00am – 9:45am    Plenary Speech: Professor Stephen Davis AO, MD  *Virtual
                   (University of Melbourne, Melbourne, Australia)

 

 

 

 

 

Professor Stephen Davis AO, MD, FRCP Edin, FRACP, FAHMS
Title of Speech: Medical and surgical trials targeting the hematoma



Professor Stephen Davis is the Professor of Translational Neuroscience at the University of Melbourne, Director of the Melbourne Brain Centre at the Royal Melbourne Hospital. He is a Past-President of the World Stroke Organization, co-chairs the Australian Stroke Alliance and the Melbourne Mobile Stroke Unit.

 

He has received numerous awards including the 2011 William Feinberg Award from the American Stroke Association, the 2012 Karolinska Award and the 2014 JJ Wepfer Award from the European Stroke Council, 2018 Stroke Leadership Award from the WSO and the 2019 Chinese Stroke Association International Cooperation Award. He was an inaugural Fellow in the Australian Academy of Health and Medical Sciences, 2015 and the 2017 C Miller Fisher Visiting Professor at the Massachusetts General Hospital/Harvard. He was appointed an Officer of the Order of Australia in 2021.

 

His research is focussed on acute therapy for both ischemic stroke and intracerebral haemorrhage, particularly the use of advanced imaging in selection of therapy. He is the Principal Investigator of a MRFF grant using tranexamic acid for intracerebral hemorrhage and Co-Lead (with G Donnan) of the 2021 Frontiers MRFF grant on Pre-Hospital Stroke Care. He has published more than 550 peer-reviewed research


Coffee break (15 min)

 

10:00am – 12:30pm   3. Theme (full session) Perivascular clearance, vasomotion, and CAA *ModeratorSusanne Van Veluw, PhD, Harvard Medical School, Boston, USA

  • MR imaging of glymphatic clearance in animal models  *Virtual
      – Helene Benveniste, MD, PhD, Yale School of Medicine, New Haven, USA
  •  
  • Anatomy of the perivascular compartment
      – Andy Shih, PhD, Center for Developmental Biology and Regenerative Medicine, University of Washington, Washington, USA
  •  
  • Physiologic drivers of lymphatic clearance
      – Deidre Jansson, MSc, PhD, School of Biological Sciences University of Auckland, Auckland, New Zealand
  •  
  • MR imaging of CSF mobility and vasomotion in humans
      – Lydiane Hirschler PhD, Leiden University Medical Center, Leiden, Netherlands
  •  
  • Selected oral abstracts – abstract 1
  • Selected oral abstracts – abstract 2
  • Selected oral abstracts – abstract 3

(3 x 10 min each)

 

12:30pm – 1:30pm    Lunch break/Poster Viewing

 

1:30pm – 2:45pm      4. Theme (half session) Innovative therapeutic approaches
*
Moderator: Samantha Gardener, PhD, Edith Cowan University, Australia

  • Fibrinolytic targets
      – Geoffrey Cloud, MD, PhD, Alfred Hospital, Melbourne, Australia
  •  
  • Cutting-Edge Therapeutic Approaches to Cerebral Amyloid Angiopathy *Virtual
      – Yasuretu Inoue, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

The neuroepidemiology of sporadic CAA, evidence from two large population-based autopsy series: the Honolulu-Asia Study and the Nun Study. *Virtual
  – Steven Edland, PhD, University of California, San Diego, USA. 
  •  

 

Coffee break (15 min)

 

3:00pm – 5:30pm       5. Theme (full session) Clinical diagnosis and treatment: ICAAA Guidelines *Moderator: Steven Greenberg, MD, PhD, Harvard Medical School, Boston, USA

Diagnosis and treatment of CAA-related inflammation/ vasculitis  *Virtual
  •   – David Werring, MD, PhD, National Hospital of Neurology and Neurosurgery, London, UK
  •  
  • Diagnosis, testing and prediction of ICH risk
  •   – Eric Smith, MD, FRCPC, MPH, University of Calgary, Calgary, Canada – 
  •  
  • Treatments/ interventions: Use of anti thrombotic agents
  •   – Karin Klijn, MD, PhD, Radboud University Medical Center, Nijmegen, Netherlands
  •  
  • Treatments/ interventions: Blood pressure, other medications, lifestyl. *Virtual
  •   – Charlotte Cordonnier MD, PhD, CHU Lille, Lille, France
  •   
  •  
  • Organisation of website, additional materials, future updating and publication
      – Susanne Van Veluw, PhD; Harvard Medical School, Boston, USA
  •   – Steven Greenberg, MD, PhD, Harvard Medical School, Boston, USA

 

5:30pm – 6:00pm: Poster Viewing

 


Day Three


8:00am – 9:00am     Poster Viewing
9:00am – 9:45am     Plenary Speech: Professor Jin-Moo Lee MD, PhD
                   (Washington University School of Medicine, Washington, USA)

 

 

Jin-Moo Lee, MD, PhD. 

Andrew B. & Gretchen P. Jones Professor

Chairman of Neurology

Neurologist in Chief, Barnes-Jewish Hospital
Title of Speech: White Matter Hyperintensity Spatial Patterns Reflect Distinct Cerebral Small Vessel Disease Pathologies

Jin-Moo Lee, MD, PhD, is the Andrew B. & Gretchen P. Jones Professor, Chairman of Neurology at Washington University School of Medicine, and Neurologist-in-Chief at Barnes-Jewish Hospital.  Dr. Lee is a physician-scientist and vascular neurologist, who has been studying the pathogenesis of stroke and Alzheimer’s disease, and the interface of these two diseases of the elderly.  His research spans the translational spectrum from cell and animal models of neurological diseases to clinical studies involving genetics and multimodal neuroimaging of patients.  Dr. Lee has published more than 200 research articles, chapters, reviews and editorials. In addition, he has been continuously funded by the NIH since 2000.  A major focus of Dr. Lee’s academic career has been research mentoring—he has mentored more than a dozen K-awardees—and has received several awards for mentorship, including the Sven Eliasson Award for Teaching Excellence and the Washington University Distinguish Faculty Mentorship Award.  In addition, he has received several awards for research excellence—most recently the Javits Neuroscience Investigator Award (R37 Merit Award).

 

Dr. Lee graduated from Yale College with a degree in Molecular Biophysics and Biochemistry, then attended Weill Cornell Medical College, earning an MD and PhD in neuroscience.  After completing residency training at the University of Pennsylvania, he completed a neurovascular fellowship at Washington University, where he subsequently joined the faculty in the Department of Neurology. 

 

Coffee break (15 min)

 

10:00am – 11:00am    6. Theme (half session) Innovative animal model systems
*
Moderator: William van Nostrand, PhD, University of Rhodes Island, Kingston, USA.  *Virtual

  • Learning dysfunction in APP Dutch mice *Virtual

  – Sam Gandy, MD, PhD, Mount Sinai, New York, USA

  •  
  • Novel rat models reveal molecular insights into the pathogenesis of CAA type-1 and CAA type-2

  – William van Nostrand, PhD, The University of Rhode Island, Kingston, USA

 

11:00am – 12:30pm    6b. Theme (half session) Fluid Biomarkers: Current and future Status
*
Moderator: Marcel Verbeek, PhD, Radboud University Medical Center, Nijmegen, Netherlands 

  • Plasma Biomarkers in AD
      – Ralph Martins, PhD, Edith Cowan University, Joondalup, Australia
  •  
  • New experimental insights from CSF studies in humans

  – Marcel Verbeek, PhD, Radboud University Medical Center, Nijmegen, Netherlands  

  •  
  • Progressive white matter injury is independently associated with cerebral amyloid angiopathy and brain atrophy

  – Jasmeer Chatwal, MD, PhD, Harvard Medical School, Boston, USA

  •  
  • Selected oral abstracts – abstract 1
  • Selected oral abstracts – abstract 2
  • Selected oral abstracts – abstract 3
    (3 x 10 min each)

 

 

12:30pm – 13:00pm Official Conference Closure
  – Susanne Van Veluw, PhD, Harvard Medical School, Boston, USA
Winners Announcements (
Students/ECR Posters and Presentations) 

 

 

1.00pm – 2.00pm    Lunch break/Poster Viewing

 

2:00pm – 4:30pm     Public Forum: CAA Community and Research:
*Moderator: Sanne van Rijn, MSC, Dorinda ‘t Hart, PhD, Maike Hoek and and Dini Plug


2:00pm – 3:00pm:


The CAA conference  is the first time ever that researchers and patient advocates from three continents (Australia, USA and Europe) are together in one room to talk about TRACK DCAA and all other things Dutch-type CAA related. This provides us with the unique opportunity to inform (Australian) family members from DCAA families about the progress in our search for an intervention to stop or slow down the disease. The interactive public forum aims to facilitate an open discussion between the researchers working on the disease and the people they are doing it for.



  1. Updates on Screening and Diagnosis, Treatment
  2. Update on Track Dutch CAA for public (From Leiden to Perth)
  3. Patient Advocates/Representatives: Sanne van Rijn (NL), Maike Hoek (NL), Dorinda ‘t Hart (AUS) and Dini Plug (AUS)

 

3:00pm – 3:30pm  Coffee Break

 

3:30pm – 4:30pm     Q&A